Analysts Offer Insights on Healthcare Companies: Cytokinetics Inc. (NASDAQ: CYTK), CRH Medical Corporation (NYSEARCA: CRHM) and Egalet Corp (NASDAQ: EGLT)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics Inc. (NASDAQ: CYTK), CRH Medical Corporation (NYSEARCA: CRHM) and Egalet Corp (NASDAQ: EGLT) with bullish sentiments.

Cytokinetics Inc. (NASDAQ: CYTK)

In a report released today, Vernon Bernardino from FBR Capital reiterated a Buy rating on Cytokinetics Inc. (NASDAQ: CYTK). The company’s shares opened today at $11.20.

According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -22.7% and a 19.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on Cytokinetics Inc. is Strong Buy and the average price target is $16, representing a 42.9% upside.

In a report released today, JMP Securities also reiterated a Buy rating on the stock.
CRH Medical Corporation (NYSEARCA: CRHM)

CRH Medical Corporation (NYSEARCA: CRHM) received a Buy rating and a $7 price target from Cantor Fitzgerald analyst Joseph France today. The company’s shares opened today at $5.40.

France commented:

“Investment summary: We are introducing coverage of CRHM with a BUY rating and $7 price target. We believe increasing numbers of gastroenterology practices will outsource anesthesia services in order to focus on clinical outcomes, improve operating efficiency and strengthen financial performance.”

According to TipRanks.com, France is a 4-star analyst with an average return of 5.0% and a 51.3% success rate. France covers the Healthcare sector, focusing on stocks such as WellCare Health Plans, Envision Healthcare, and Acadia Healthcare.

CRH Medical Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $7.

Egalet Corp (NASDAQ: EGLT)

In a report released today, Chiara Russo from Cantor Fitzgerald reiterated a Buy rating on Egalet Corp (NASDAQ: EGLT), with a price target of $21. The company’s shares opened today at $6.92.

Russo wrote:

“EGLT announced this afternoon the filing of an sNDA for Oxaydo, to expand the label to include abuse-deterrent language around intravenous abuse.”

According to TipRanks.com, Russo is ranked 0 out of 5 stars with an average return of -4.2% and a 39.0% success rate. Russo covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Axsome Therapeutics Inc, and Flexion Therapeutics.

Egalet Corp has an analyst consensus of Moderate Buy.